Eloxx Pharmaceuticals Inc (NASDAQ:ELOX)
| 0.1704 Delayed Data As of Sep 30 |  +0.0189 / +12.48%Today’s Change | 0.14 Today|||52-Week Range 1.66 | -75.87% Year-to-Date |
Latest ELOX News | Press Releases
| Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More Sep 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.15 |
| Today’s open | 0.16 |
| Day’s range | 0.16 - 0.17 |
| Volume | 512 |
| Average volume (3 months) | 222,693 |
| Market cap | $15.2M |
Data as of 4:01pm ET, 09/30/2022
Growth & Valuation
| Earnings growth (last year) | -10.69% |
| Earnings growth (this year) | +50.53% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 0.68 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CALACalithera Bioscience... | +0.04 | +1.35% |
| APVOAptevo Therapeutics ... | +0.10 | +3.39% |
| CBIOCatalyst Biosciences... | -0.00 | -0.90% |
| TMBRTimber Pharmaceutica... | +0.01 | +10.44% |
Data as of 4:01pm ET, 09/30/2022
Financials
| Next reporting date | November 10, 2022 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$66.7M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Watertown, Massachusetts |
Forecasts
